Sugi Predict

Sugi Predict / Compounds / Valconazole

Valconazole

Valconazole

SCHEMBL1258175

CC(C)(C)C(=O)C(Cn1ccnc1)Oc1ccc(Cl)cc1Cl

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.59
▸ CYP2C9 P11712 2/20 0.59
▸ ADRA2C P18825 1/20 0.50
▸ USP2 O75604 1/20 0.49
▸ ALOX12 P18054 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ LMNA P02545 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ SLC6A4 P31645 1/20 0.47
▸ ADRA1A P35348 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ IDO1 P14902 1/20 0.46
▸ MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valconazole SCHEMBL11381699 0.99 CYP3A4 (0.58) CYP3A4CYP2C9ADRA2CUSP2ALOX12
Hydrochloric Acid SCHEMBL11073327 0.90 CYP3A4 (0.47) CYP3A4CYP2C9ADRA2CUSP2ALOX12
SCHEMBL11833089 0.84 CYP3A4 (0.62) CYP3A4CYP2C9LMNAMEN1ADORA3
SCHEMBL11838768 0.80 CYP2C9 (0.61) CYP3A4CYP2C9ADRA2CUSP2ALOX12
SCHEMBL11079790 0.80 PPARA (0.52) CYP3A4CYP2C9ALOX12MAPK1LMNA
SCHEMBL11367322 0.77 CYP3A4 (0.53) CYP3A4CYP2C9ADRA2CUSP2ALOX12
SCHEMBL11335164 0.77 CYP2C9 (0.58) CYP3A4CYP2C9ADRA2CUSP2ALOX12
SCHEMBL11715575 0.75 SMN1; SMN2 (0.47) CYP3A4CYP2C9ALOX12MAPK1LMNA
SCHEMBL11356894 0.74 PPARA (0.56) USP2MAPK1LMNASMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL11710846 0.74 SMN1; SMN2 (0.46) CYP3A4CYP2C9ALOX12MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20040254182-A1 Enhanced propertied pharmaceuticals ROHM AND HAAS COMPANY 2004-12-16 — — US claimed
CN-1441790-A Enhanced propertied pharmaceuticals ROHM & HAAS (US) 2003-09-10 — — CN claimed
EP-1272463-A1 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2003-01-08 — — EP claimed
WO-2001054481-A2 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2001-08-02 — — WO claimed
CN-1119824-A Fungicidal mixture BASF AG (DE) 1996-04-03 — — CN claimed
EP-0004918-B1 OPTICALLY ACTIVE (-)-2-(2,4-DICHLOROPHENOXY)-1-(IMIDAZOL-1-YL)-4,4-DIMETHYL-PENTAN-3-ONE PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BAYER AG (DE) 1981-09-23 — — EP claimed
CN-114965759-A Kit and method for detecting 32 antibiotics based on LC-MS/MS 杭州度安医学检验实验室有限公司 2022-08-30 — — CN disclosed
CN-114929201-A Co-amorphous form of beta-lactoglobulin and a drug 泽里翁制药公司 2022-08-19 — — CN disclosed
CN-114230571-A Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof 无限药品股份有限公司 2022-03-25 — — CN disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
EP-0004918-B1 OPTICALLY ACTIVE (-)-2-(2,4-DICHLOROPHENOXY)-1-(IMIDAZOL-1-YL)-4,4-DIMETHYL-PENTAN-3-ONE PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BAYER AG (DE) 1981-09-23 — — EP disclosed
EP-0004918-A1 Optically active (-)-2-(2,4-dichlorophenoxy)-1-(imidazol-1-yl)-4,4-dimethyl-pentan-3-one process for its preparation and pharmaceutical compositions containing them BAYER AG (DE) 1979-10-31 — — EP disclosed
EP-0004918-A1 Optically active (-)-2-(2,4-dichlorophenoxy)-1-(imidazol-1-yl)-4,4-dimethyl-pentan-3-one process for its preparation and pharmaceutical compositions containing them BAYER AG (DE) 1979-10-31 — — EP disclosed
EP-0004918-A1 Optically active (-)-2-(2,4-dichlorophenoxy)-1-(imidazol-1-yl)-4,4-dimethyl-pentan-3-one process for its preparation and pharmaceutical compositions containing them BAYER AG (DE) 1979-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254182-A1 Enhanced propertied pharmaceuticals ABCB1, ABCB11, ABCG2 CYP3A4 81/4885CYP2C9 20/4885ADRA2C 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.